Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring

Sanofi’s PCSK9 inhibitor Praluent (alirocumab) will be delisted from the NHI reimbursement price list in Japan at the end of this fiscal year after it was pulled from the market following the company’s loss in a patent suit filed by...read more